%0 Journal Article
%T Cross-validation of optimized composites for preclinical Alzheimer's disease
%A Australian Imaging Biomarkers and Lifestyle
%A Chung-Kai Sun
%A Japanese Alzheimer's Disease Neuroimaging Initiative
%A North American Alzheimer's Disease Neuroimaging Initiative
%A Paul S. Aisen
%A Philip S. Insel
%A Rema Raman
%J Archive of "Alzheimer's & Dementia : Translational Research & Clinical Interventions".
%D 2017
%R 10.1016/j.trci.2016.12.001
%X We discuss optimization and validation of composite end points for presymptomatic Alzheimer's disease clinical trials. Optimized composites offer hope of substantial gains in statistical power or reduction in sample size. But there is tradeoff between optimization and face validity such that optimization should only be considered if there is a convincing rationale. As with statistically derived regions of interest in neuroimaging, validation on independent data sets is essential
%K Preclinical Alzheimer's disease
%K Cognitive composites
%K End-point validation
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5527287/